Medicare proposes to limit coverage of Biogen Alzheimer's drug

Medicare will restrict coverage of Biogen's controversial Alzheimer's treatment only to patients who take part in a rigorous clinical trial, the federal government announced Tuesday, a decision that would likely keep use of the drug low if finalized later this year.